Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.59 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.59 |
| ▸ | ALDH2 | P05091 | 12/20 | 0.57 |
| ▸ | MAOA | P21397 | 5/20 | 0.57 |
| ▸ | MAOB | P27338 | 5/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3663496 | 0.91 | PDK1 (0.62) | PDK1PDK2HRH3ALDH2MAOA | |
| SCHEMBL3666417 | 0.90 | PDK1 (0.62) | PDK1PDK2HRH3ALDH2MAOA | |
| SCHEMBL2108439 | 0.89 | PDK1 (0.63) | PDK1PDK2HRH3ALDH2MAOA | |
| SCHEMBL3665391 | 0.88 | PDK1 (0.62) | PDK1PDK2HRH3ALDH2MAOA | |
| SCHEMBL3665670 | 0.88 | PDK1 (0.62) | PDK1PDK2HRH3ALDH2MAOA | |
| SCHEMBL2108495 | 0.85 | PDK1 (0.65) | PDK1PDK2HRH3ALDH2MAOA | |
| SCHEMBL3666748 | 0.85 | PDK1 (0.60) | PDK1PDK2HRH3ALDH2MAOA | |
| SCHEMBL3665418 | 0.83 | PDK1 (0.65) | PDK1PDK2HRH3ALDH2MAOA | |
| SCHEMBL2107141 | 0.83 | HRH3 (0.66) | PDK1PDK2HRH3ALDH2MAOA | |
| SCHEMBL3665718 | 0.82 | PDK1 (0.63) | PDK1PDK2HRH3ALDH2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231149-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | CV Therapeutics Inc. (US) | 2010-09-29 | — | — | EP | claimed |
| US-20090209533-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2009-08-20 | — | — | US | claimed |
| US-20090124672-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | AMYGDALA NEUROSCIENCES, INC. | 2009-05-14 | — | — | US | claimed |
| WO-2009061924-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | CV THERAPEUTICS, INC. (US) | 2009-05-14 | — | — | WO | claimed |
| EP-2046769-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | CV THERAPEUTICS, INC. (US) | 2009-04-15 | — | — | EP | claimed |
| US-20080032995-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2008-02-07 | — | — | US | claimed |
| WO-2008014497-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | CV THERAPEUTICS, INC. (US) | 2008-01-31 | — | — | WO | claimed |
| US-8158810-B2 | ALDH-2 inhibitors in the treatment of addiction | GILEAD SCIENCES, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| EP-2254878-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | Gilead Palo Alto, Inc. (US) | 2010-12-01 | — | — | EP | disclosed |
| EP-2231149-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | CV Therapeutics Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090209533-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2009-08-20 | — | — | US | disclosed |
| WO-2009094028-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | CV THERAPEUTICS, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| US-20090124672-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | AMYGDALA NEUROSCIENCES, INC. | 2009-05-14 | — | — | US | disclosed |
| WO-2009061924-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | CV THERAPEUTICS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| EP-2046769-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | CV THERAPEUTICS, INC. (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080207610-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080032995-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2008-02-07 | — | — | US | disclosed |
| WO-2008014497-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | CV THERAPEUTICS, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207610-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | ALDH1A1, ADH1A, ALDH3A1 | PDK1 201/4885PDK2 68/4885HRH3 2871/4885 |
| US-20090209533-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | ALDH1A1, ADH1A, ALDH3A1 | PDK1 201/4885PDK2 68/4885HRH3 2871/4885 |
| US-20080032995-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION | ALDH1A1, ADH1A, ALDH3A1 | PDK1 167/4885PDK2 52/4885HRH3 2762/4885 |
| US-20090124672-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | ALDH2, ALDH1A2, ALDH1A1 | PDK1 211/4885PDK2 40/4885HRH3 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.